Biggest News Aggregation in the World
📰 Impacts Questionnaire News

Page 2 - Impacts Questionnaire News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Impacts Questionnaire. Real-time updates on events, politics, business and more.

SLEEP 2022: Idorsia U.S. to present data from Wake Up America survey, revealing the hidden toll of insomnia, along with three other abstracts on the evaluation and treatment of insomnia

Poster presentation of Wake Up America: The Night & Day Impact of Insomnia, the largest U.S. survey of people with trouble sleeping and doctors, to discover...
United States Switzerland General Andrewc Weiss Michael Grandner Octavia Spencer Charlene Gamaldo

Idorsia Pharmaceuticals Ltd: Europe's first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

QUVIVIQ? is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningComprehensive nighttime
Switzerland General United States France General United Kingdom Northern Ireland Great Britain

Idorsia Pharmaceuticals Ltd: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for QUVIVIQ (daridorexant) for the treatment of adult patients
United States Switzerland General United Kingdom Sri Lanka Northern Ireland Baylor College Of Medicine

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Idorsia Ltd (SIX: IDIA) today announced the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of QUVIVIQ™ (daridorexant) as the first dual orexin receptor antagonist in the European Union (EU) for the t...
United States Switzerland General United Kingdom Sri Lanka Northern Ireland Baylor College Of Medicine

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science